<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01067274</url>
  </required_header>
  <id_info>
    <org_study_id>ALFA-0703 Study - P060205</org_study_id>
    <nct_id>NCT01067274</nct_id>
  </id_info>
  <brief_title>ALFA-0703 Study in Older Patients With Acute Myeloblastic Leukemia (AML)</brief_title>
  <acronym>ALFA-0703</acronym>
  <official_title>A Randomized Multicenter Phase III Study to Evaluate the Role of All-trans Retinoic Acid (ATRA) in Combination With Induction Chemotherapy, or Azacitidine and Idarubicin as Salvage Therapy and Idarubicin With Cytarabine or Azacitidine as Maintenance Therapy in Older Patients With Acute Myeloblastic Leukemia (AML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acute Leukemia French Association</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Acute Leukemia French Association</source>
  <brief_summary>
    <textblock>
      A Randomized Multicenter Phase III Study to Evaluate the Role of All-trans Retinoic Acid
      (ATRA) in Combination with Induction Chemotherapy, or Azacitidine and Idarubicin as salvage
      therapy and Idarubicin with Cytarabine or Azacitidine as Maintenance Therapy in Older
      Patients with Acute Myeloblastic Leukemia (AML).

      To compare the outcome of elderly patients with newly-diagnosed AML treated with standard
      induction chemotherapy and post-remission therapy, in only patients in CR, with either
      azacitidine or cytarabine combined to idarubicin +/- ATRA and salvage therapy with
      azacitidine combined to idarubicin +/- ATRA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Induction therapy :

      First randomization (R1) at baseline : ATRA versus no ATRA.

      Salvage therapy :

      No conventional salvage therapy is planned. Patients who will not achieve CR, according to
      IWG criteria after induction will be treated with 3 courses of azacitidine and idarubicin +/-
      ATRA combination, if eligible for further treatment.

      Followed by 3 identical courses and 6 courses of maintenance by azacitidine alone to be
      delivered every 28 days, in those patients reaching CR or PR after 3 courses (evaluation of
      response from 28 to 56 days from course 3).

      Randomization R2: type of maintenance:

      Response to induction will be evaluated 2 weeks after myeloid recovery, just before first
      consolidation course, due use of to pegfilgrastim, lenograstim or filgrastim during
      induction.

      Responses will be classified according to the Revised Recommendations of the IWG for AML.

      Patients in CR only will be subjected to a second randomization R2 as follows 6 courses of
      combined chemotherapy, will be delivered as outpatients, ATRA according to R1 randomization.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study abandoned
  </why_stopped>
  <start_date>April 2010</start_date>
  <primary_completion_date type="Anticipated">April 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>For randomization R1, the primary endpoint is Event-free Survival (EFS)</measure>
    <time_frame>2-year EFS</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>For randomization R2, the primary endpoint is disease free survival (DFS)</measure>
    <time_frame>2-year DFS</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete Response (CR) rate</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate to azacitidine idarubicin +/-ATRA combination after intensive chemotherapy failure and identification of possible predictors of response to this therapy</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the safety of combination ATRA + chemotherapy or idarubicin-azacitidine courses and of maintenance with azacitidine</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects on relapse rates of ATRA and maintenance, with respect to cytogenetics risk groups, subtypes of AML and mutational status (FLT3, MLL), and biomarkers</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>R1 Arm A : ATRA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Idarubicin: 9 mg/m2/d D1 to D4 Cytarabine : 200 mg/m2/d Continuous IV from D1 to D7 Peg-filgrastim : 6 mg SC D9 or filgrastim 5ug/kg/d SC or lenograstim 263ug/d IV 30mn, both from D9 to myeloid recovery(PMN &gt;1G/l over 2 days at minimum
All-trans retinoic acid (ATRA): 45mg/m2/day in two divided doses from D8 to D28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R1 Arm B : no ATRA</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Idarubicin: 9 mg/m2/d D1 to D4 Cytarabine : 200 mg/m2/d Continuous IV from D1 to D7 Peg-filgrastim : 6 mg SC D9 or filgrastim 5ug/kg/d SC or lenograstim 263ug/d IV 30mn, both from D9 to myeloid recovery(PMN &gt;1G/l over 2 days at minimum</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R2 Arm 1A : AZACITIDINE and ATRA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Azacitidine: 75 mg/m2/12h SC from D1 to D5 Idarubicine: 9 mg/m2/d IV on D5 All-trans retinoic acid (ATRA): 45mg/m2/d in two divided doses from D8 to D21</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R2 Arm 1B : AZACITIDINE and No ATRA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Azacitidine: 75 mg/m2/12h SC from D1 to D5 Idarubicine: 9 mg/m2/d IV on D5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R2 Arm 2A : ATRA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Idarubicine : 9 mg/m2/d IV on D1 Cytarabine : 60 mg/m2/12h SC from D1 to D5 All-trans retinoic acid (ATRA): 45mg/ m2/d in two divided doses from D8 to D21</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R2 Arm 2B : no ATRA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Idarubicine : 9 mg/m2/d IV on D1 Cytarabine : 60 mg/m2/12h SC from D1 to D5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vesanoid (ATRA)</intervention_name>
    <description>45 mg/m2/day in two divided doses from D8 to D28</description>
    <arm_group_label>R1 Arm A : ATRA</arm_group_label>
    <arm_group_label>R2 Arm 1A : AZACITIDINE and ATRA</arm_group_label>
    <arm_group_label>R2 Arm 2A : ATRA</arm_group_label>
    <other_name>VEZANOIDE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZACITIDINE (VIDAZA)</intervention_name>
    <description>75 mg/m2/12h SC from D1 to D5</description>
    <arm_group_label>R2 Arm 1A : AZACITIDINE and ATRA</arm_group_label>
    <arm_group_label>R2 Arm 1B : AZACITIDINE and No ATRA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CYTARABINE</intervention_name>
    <description>Cytarabine : 60 mg/m2/12h SC from D1 to D5</description>
    <arm_group_label>R2 Arm 2A : ATRA</arm_group_label>
    <arm_group_label>R2 Arm 2B : no ATRA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged of 65 to 79 years

          2. With a morphologically proven diagnosis of AML according to WHO classification either
             de novo or AML with &quot;myelodysplasia related changes&quot;

          3. Not previously treated for AML

          4. Signed informed consent.

        Exclusion Criteria:

          1. APL in the WHO classification.

          2. Ph1-positive AML or prior Ph1-positive disease

          3. AML evolving from a prior MPN in the WHO 2008 classification.

          4. Prior treatment with chemotherapy or radiotherapy for another tumor

          5. Prior tumor, if not stable for at least two years, except in-situ carcinoma and skin
             carcinoma

          6. Prior advanced malignant hepatic tumor

          7. ECOG Performance Status Score &gt; 2

          8. Creatinine level more than 2x's the upper limit of the normal range (ULN) at the
             laboratory where the analysis was performed, except if AML-related.

          9. Total serum bilirubin more than 2x's the ULN at the laboratory where the analysis was
             performed, except if AML-related.

         10. AST (SGOT) or ALT (SGPT) more than 2.5x's the ULN at the laboratory where the analysis
             was performed, except if AML-related

         11. LVEF less than.55 or equivalent by doppler echocardiography

         12. Known intolerance to Azacitidine, mannitol, retinoids

         13. Positive serum test for HIV and HTLV-1

         14. NYHA Grade 3/4 cardiac disease .

         15. Severe infection at inclusion time.

         16. Psychiatric disease or an history of non-compliance to medical regimens or patients
             considered potentially unreliable.

         17. Absence of health care insurance (affiliation à un régime de Sécurité Sociale)

         18. Participation to any study requiring informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GARDIN CLAUDE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Acute Leukemia French Association</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chu Amiens Sud</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Argenteuil</city>
        <zip>95107</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Boulogne Sur Mer</name>
      <address>
        <city>Boulogne Sur Mer</city>
        <zip>62321</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Percy</name>
      <address>
        <city>Clamart</city>
        <zip>92141</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ch Sud Francilien</name>
      <address>
        <city>Corbeil Essonnes</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ch Dunkerque</name>
      <address>
        <city>Dunkerque</city>
        <zip>59385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Lens</city>
        <zip>62307</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Meaux</city>
        <zip>77104</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Necker Hospital</name>
      <address>
        <city>Paris 15</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Antoine Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Pitie-Salpetriere</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ch Rene Dubos</name>
      <address>
        <city>Pontoise</city>
        <zip>95303</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Roubaix</city>
        <zip>59100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CNLCC</name>
      <address>
        <city>Saint-Cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Valenciennes</city>
        <zip>59322</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Versailles</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IGR</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2010</study_first_submitted>
  <study_first_submitted_qc>February 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2010</study_first_posted>
  <last_update_submitted>December 29, 2015</last_update_submitted>
  <last_update_submitted_qc>December 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2015</last_update_posted>
  <responsible_party>
    <name_title>Dr Claude GARDIN</name_title>
    <organization>Avicenne Hospital- Hôpital Avicenne, AP-HP Bobigny</organization>
  </responsible_party>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>Aged of 65 to 79 years</keyword>
  <keyword>Older Patients with Acute Myeloblastic Leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
    <mesh_term>Tretinoin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

